Rheumatoid Arthritis Clinical Studies

You have full text access to this OnlineOpen article

Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies

  1. Elizabeth W. Karlson1,*,
  2. Lori B. Chibnik1,
  3. Shelley S. Tworoger2,
  4. I-Min Lee2,
  5. Julie E. Buring2,
  6. Nancy A. Shadick1,
  7. JoAnn E. Manson2,
  8. Karen H. Costenbader1

Article first published online: 26 FEB 2009

DOI: 10.1002/art.24350

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 3, pages 641–652, March 2009

Additional Information

How to Cite

Karlson, E. W., Chibnik, L. B., Tworoger, S. S., Lee, I.-M., Buring, J. E., Shadick, N. A., Manson, J. E. and Costenbader, K. H. (2009), Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis & Rheumatism, 60: 641–652. doi: 10.1002/art.24350

Author Information

  1. 1

    Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

  2. 2

    Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts

*Brigham and Women's Hospital, Division of Rheumatology, Allergy, and Immunology, 75 Francis Street, PBB-3, Boston, MA 02115

Publication History

  1. Issue published online: 26 FEB 2009
  2. Article first published online: 26 FEB 2009
  3. Manuscript Accepted: 25 NOV 2008
  4. Manuscript Received: 8 JUL 2008

Funded by

  • NIH. Grant Numbers: R01-AR-49880, R01-CA-87969, R01-HL-43851, R01-CA-47988, P60-AR-047782, K24-AR-052401
  • NIH grant from the National Institute of Mental Health. Grant Number: BIRCWH K12-HD-051959
  • National Institute of Allergy and Infectious Disease
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Office of the Director
  • Arthritis Foundation/American College of Rheumatology Arthritis Investigator Award
  • Katherine Swan Ginsburg Memorial Award
  • Amgen
  • Bristol-Myers Squibb Foundation
  • Biogen Idec
  • Crescendo Therapeutics
  • Dow Corning

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (119K)

REFERENCES

  • 1
    Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205–13.
    Direct Link:
  • 2
    Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75: 330–7.
  • 3
    Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis —a genomewide study. N Engl J Med 2007; 357: 1199–209.
  • 4
    Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977–86.
  • 5
    Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39: 1477–82.
  • 6
    Vessey MP, Villard-Mackintosh L, Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception 1987; 35: 457–64.
  • 7
    Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis 1990; 49: 980–2.
  • 8
    Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993; 20: 1830–5.
  • 9
    Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994; 5: 525–32.
  • 10
    Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care–based incident case–control study in Norfolk, England. Arthritis Rheum 1997; 40: 1955–61.
    Direct Link:
  • 11
    Uhlig T, Hagen KB, Kvien TK. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol 1999; 26: 47–54.
  • 12
    Krishnan E, Sokka T, Hannonen P. Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther 2003; 5: R158–62.
  • 13
    Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835–41.
  • 14
    Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A gene–environment interaction between smoking and shared epitope genes in HLA–DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50: 3085–92.
    Direct Link:
  • 15
    Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006; 119: 503.e1–9.
  • 16
    Brennan P, Bankhead C, Silman A, Symmons D. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 1997; 26: 817–23.
  • 17
    Hannaford PC, Kay CR, Hirsch S. Oral contraceptives and rheumatoid arthritis: new data from the Royal College of General Practitioners' oral contraception study. Ann Rheum Dis 1990; 49: 744–6.
  • 18
    Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum 2004; 50: 3458–67.
    Direct Link:
  • 19
    Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741–9.
    Direct Link:
  • 20
    Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380–6.
    Direct Link:
  • 21
    Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? [editorial]. Arthritis Rheum 2003; 48: 2701–5.
    Direct Link:
  • 22
    Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001; 108: 1417–22.
  • 23
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–33.
  • 24
    Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis [review]. Annu Rev Immunol 1996; 14: 397–440.
  • 25
    Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160–9.
    Direct Link:
  • 26
    Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995; 22: 406–12.
  • 27
    Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1438–43.
  • 28
    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 2003; 21: 63–9.
  • 29
    Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999; 33: 1935–42.
  • 30
    Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–304.
  • 31
    Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 56–65.
  • 32
    Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47–55.
  • 33
    Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 783–8.
  • 34
    Karlson EW, Sanchez-Guerrero J, Wright EA, Lew RA, Daltroy LH, Katz JN, et al. A connective tissue disease screening questionnaire for population studies. Ann Epidemiol 1995; 5: 297–302.
  • 35
    Karlson EW, Costenbader KH, McAlindon TE, Massarotti EM, Fitzgerald LM, Jajoo R, et al. High sensitivity, specificity and predictive value of the Connective Tissue Disease Screening Questionnaire among urban African-American women. Lupus 2005; 14: 832–6.
  • 36
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 37
    Liang MH, Meenan RF, Cathcart ES, Schur PH. A screening strategy for population studies in systemic lupus erythematosus: series design. Arthritis Rheum 1980; 23: 153–7.
    Direct Link:
  • 38
    Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm EB. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem 2002; 48: 1781–4.
  • 39
    Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66: 712–9.
  • 40
    Dorner RW, Alexander RL Jr, Moore TL. Rheumatoid factors. Clin Chim Acta 1987; 167: 1–21.
  • 41
    Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol 1978; 108: 299–307.
  • 42
    Shadick NA, Cook NR, Karlson EW, Ridker PM, Maher NE, Manson JE, et al. C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 2006; 166: 2490–4.
  • 43
    Glynn RJ, Rosner B. Methods to evaluate risks for composite end points and their individual components. J Clin Epidemiol 2004; 57: 113–22.
  • 44
    Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007; 25: 1482–8.
  • 45
    Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8: R133.
  • 46
    Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cut-points and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future RA. J Rheumatol 2009. In press.
  • 47
    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.
  • 48
    Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004; 50: 2423–7.
    Direct Link:
  • 49
    Masi AT, Aldag JC, Sipes J. Do elevated levels of serum C-reactive protein predict rheumatoid arthritis in men: correlations with pre-RA status and baseline positive rheumatoid factors. J Rheumatol 2001; 28: 2359–61.
  • 50
    Aho K, Palosuo T, Knekt P, Alha P, Aromaa A, Heliovaara M. Serum C-reactive protein does not predict rheumatoid arthritis. J Rheumatol 2000; 27: 1136–8.
  • 51
    Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002; 46: 654–62.
    Direct Link:
  • 52
    Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521–8.
  • 53
    Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 3444–9.
    Direct Link:
  • 54
    Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3940–8.
    Direct Link:
  • 55
    Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38–46.
    Direct Link:
  • 56
    Gottlieb PA, Eisenbarth GS. Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med 1998; 49: 391–405.
  • 57
    Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685–91.
  • 58
    Gardner SG, Gale EA, Williams AJ, Gillespie KM, Lawrence KE, Bottazzo GF, et al. Progression to diabetes in relatives with islet autoantibodies. Is it inevitable? Diabetes Care 1999; 22: 2049–54.
  • 59
    Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006; 65: 535–7.
  • 60
    Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003; 108: 155–60.
  • 61
    Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women: incidence rates in group health cooperative, Seattle, Washington, 1987–1989. Arthritis Rheum 1991; 34: 1502–7.
    Direct Link:
  • 62
    Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111: 87–98.
  • 63
    Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999; 42: 415–20.
    Direct Link:
View Full Article (HTML) Get PDF (119K)